Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients

by Vandana Singh, Benzinga Editor

September 2, 2021 10:59 AM | 1 min read | Make a Comment

Pfizer Inc PFE has initiated a Phase 3 clinical trial evaluating its respiratory syncytial virus (RSV) bivalent prefusion F subunit investigational vaccine candidate (RSVpreF) in adults ages 60 years or older.
The Phase 3 RENOIR trial will enroll approximately 30,000 participants 60 years and older.
The study's primary objectives will assess safety and efficacy for preventing moderate to severe lower respiratory tract illness (msLRTI-RSV) during the first RSV season.
Related Content: Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US
Price Action: PFE stock is up 0.53% at $46.29 during the premarket session on the last check Thursday.

Posted In: Biotech News Health Care General Briefs Phase 3 Trial REspiratory syncytial virus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.